Cargando…

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas

BACKGROUND: IDH mutation is the main factor used in the prognostication of diffuse gliomas, however within IDH mutated gliomas there still remains a high variability in both tumor progression and overall survival.(1) Digital droplet polymerase chain reaction (ddPCR) is one of the latest molecular am...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voisin, Mathew, Zadeh, Gelareh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255456/ http://dx.doi.org/10.1093/noajnl/vdab070.016

Ejemplares similares

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis
por: Aghaei, Nikoo, et al.
Publicado: (2021)

NGMA-6. Quantitative MGMT Promoter Methylation Index Indicates Non-Linear, Prognostic Effect in Glioblastoma
por: Gibson, David, et al.
Publicado: (2021)

NGMA-3. Use of multi-omics data to initialize and validate a causal model of glioblastoma stem cell signaling
por: Holtzapple, Emilee, et al.
Publicado: (2021)

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
por: Shi, Diana D, et al.
Publicado: (2021)

NI-13 Prediction of outcome at the time of discontinuing TMZ-adjuvant therapy in IDH-mutant lower grade glioma using (11)C-methinine PET
por: Beppu, Takaaki, et al.
Publicado: (2021)

BIMG-15. LACTATE AND GLUTATHIONE LEVELS DETECTED WITH PROTON MR SPECTROSCOPY ARE ASSOCIATED WITH POOR SURVIVAL IN IDH WILD TYPE TERTP MUTANT DIFFUSE GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

NGMA-2. Dual sgRNA-directed PD-L1 knockout in human glioblastoma cells using the CRISPR/Cas9 system
por: Fierro, Javier, et al.
Publicado: (2021)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS
por: Li, Xianqi, et al.
Publicado: (2021)

BIMG-20. METABOLIC BIOMARKERS IN MICRODIALYSATE OF IDH-1 MUTANT TUMORS
por: Rajani, Karishma, et al.
Publicado: (2021)

NGMA-4. Creation of a MADR brain tumor single-cell atlas for examination of inter-/intratumor heterogeneity and the results of genetic perturbations in a diverse array of brain tumor subtypes
por: Pacheco, David Rincon Fernandez, et al.
Publicado: (2021)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
por: Sanada, Takahiro, et al.
Publicado: (2021)

ACT-5 Prognosis of IDH-mut lower-grade gliomas in Hokkaido University Hospital
por: Yamaguchi, Shigeru, et al.
Publicado: (2021)

BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO
por: Taglang, Celine, et al.
Publicado: (2021)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
por: Marks, Asher, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling
por: Zuccato, Jeffrey, et al.
Publicado: (2021)

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant
por: Yano, Hirohito, et al.
Publicado: (2021)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

MPC-7 Clinical features of Diffuse hemispheric glioma, H3 G34-mutant in children and young adults
por: Takeshima, Yuki, et al.
Publicado: (2021)

DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
por: Kayabölen, Alişan, et al.
Publicado: (2021)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

BIMG-14. IDENTIFICATION OF IDH MUTATION STATUS USING PROTON MR SPECTROSCOPY AND MASS SPECTROMETRY: A STUDY OF 178 GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

CS-12 IDH-1 MUTANT GLIOMA IN BROTHER AND SISTER, ONSET AT AGE OF 30s
por: Kitai, Ryuhei, et al.
Publicado: (2019)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

MPC-5 Characteristics of H3 G34-mutant gliomas
por: Kibe, Yuji, et al.
Publicado: (2021)

NI-10 Reclassification of diffuse gliomas based on molecular diagnosis -evaluation of methionine uptake and treatment outcome-
por: Tamura, Kaoru, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

BT-1 An autopsy case of multicentric malignant glioma, H3K27M mutant
por: Hayashi, Nobuhide, et al.
Publicado: (2021)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sfp6ae3sjtbtt6eb1mtoqpic6o